All In Biotech

Drug Trial Radar · NCT06401356

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With Pelabresib

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Aug 13, 2024

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).

Conditions

  • Hematologic Malignancy
  • Solid Tumor
  • Advanced Malignancies

Interventions

  • PelabresibDrug

    Small molecule inhibitor of bromodomain and extraterminal (BET) protein

  • RuxolitinibDrug

    Small molecule selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs) and serious TEAEsTime frame: 5 years
  2. Survival Follow-upTime frame: 5 years
  3. Duration of Response (DoR)Time frame: 5 years
  4. Progression-free survival (PFS)Time frame: 5 years
  5. Leukemia-free survival (LFS)Time frame: 5 years

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California LA

    Los Angeles, California · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Uni Of Michigan Health System

    Ann Arbor, Michigan · Recruiting

  • New York Presbyterian Hospital

    New York, New York · Recruiting

  • Mt Sinai Medical Center

    New York, New York · Recruiting

  • Novartis Investigative Site

    Antwerp, Belgium · Recruiting

  • Novartis Investigative Site

    Bruges, Belgium · Recruiting

  • Novartis Investigative Site

    Novara, Italy · Recruiting

  • Novartis Investigative Site

    Florence, FI, Italy · Recruiting

  • Novartis Investigative Site

    Varese, VA, Italy · Recruiting

  • Novartis Investigative Site

    Amsterdam, Netherlands · Recruiting

  • Novartis Investigative Site

    Cardiff, United Kingdom · Recruiting

  • Novartis Investigative Site

    Glasgow, United Kingdom · Recruiting

  • Novartis Investigative Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.